That includes Lilly's Alzheimer's candidates, currently headed by amyloid-targeting drug donanemab which was ... facility for active pharmaceutical ingredients (APIs) in Dublin, creating 100 ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Last month, the FDA granted approval to Eli Lilly’s donanemab - or Kisunla - for the treatment of Alzheimer’s disease. Its approval was based on the treatment demonstrating what the FDA ...

After hours: February 3 at 6:27:16 PM EST Loading Chart for MGPI ...

Sure, a frozen tub of sugary slush from the corner store might do in a pinch, but when you want ice cream that's worth savoring—silky texture, complex flavors, and ingredients you can actually ...

View the live stream, or join us through our Webex meeting link, starting at 7:50 a.m. Wednesday Oregon Health & Science University is dedicated to improving the health and quality of life for all ...

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...